Tag Archives: Peter Breggin

One Million Kids on Anti-Psychotics

In July, the Washington Post reported that Corporate America is hoarding a record $1.8 trillion in cash while it waits for profit-making opportunities. At the same time, record numbers of American children are being prescribed toxic psychiatric drugs at earlier ages. These two facts are connected. The corporate class stole its trillions from us, by exploiting workers at home and abroad – paying us less than our labor is worth – and by laying off workers and squeezing the rest to work a lot harder for much less.

Overmedication contributes to military suicides, advocates say

The suicide rate among military veterans has ballooned in recent years, in part because of overmedication of service members and a lack of support for veterans, advocates for treatment of Post Traumatic Stress Disorder said Thursday. Psychiatrists sometimes prescribe drugs as a cure without an actual understanding of what the drugs do, said Dr. Peter R. Breggin, a psychiatrist and author from Ithaca, N.Y.

Psychiatric drug use skyrockets in U.S. military

Use of prescription psychotropics has skyrocketed among U.S. military personnel in recent years, according to an investigation by Military Times. At least 17 percent of active-duty military personnel are currently taking an antidepressant, including as many as 6 percent of all deployed troops. In contrast, the rate of antidepressant use in the wider U.S. public is only 10 percent.

SSRIs Render Unfriendly Skies—FOIA documents reveal what FAA failed to consider in allowing pilots on antidepressants to fly

The SSRI antidepressant makers are desperate to find new customers, so they recently have been focusing on capturing groups for which the drugs were usually considered off limits. The latest marketing coup managed to open up sales to roughly 614,000 American pilots. Under a new policy announced on April 5, 2010, pilots diagnosed with depression can seek permission from the Federal Aviation Administration to take one of four SSRIs, including Eli Lilly’s Prozac, Pfizer’s Zoloft, and Forest Laboratories’ Celexa and Lexapro.